This is from various wires and news sources:
A study and an editorial published in Circulation, the medical journal of the American Heart Association, raise concerns about whether Natrecor, an intravenous heart failure drug sold by Johnson & Johnson, is safe for the kidneys.
Natrecor is viewed as a promising treatment for acute heart failure. Heart failure, where the heart loses the ability to pump enough blood.
The author of the studay is Jonathan Sackner-Bernstein, the director of the clinical research at North Shore University Hospital in Manhasset, N.Y.
The Sackner-Bernstein paper includes studies done at doses higher than are advised on the drug's label.
